Financial News

J&J Pharmaceutical Sales up 14% in the Quarter

COVID-19 Vaccine contributes $502 million in sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 3Q Revenues: $23.3 billion (+11%) 3Q Earnings: $3.7 billion (+3%) YTD Revenues: $69.0 billion (+15%) YTD Earnings: $16.1 billion (+24%) Comments: Pharmaceutical sales were $13.0 billion in the quarter, up 14% driven by DARZALEX for the treatment of multiple myeloma, STELARA, a biologic for immune-mediated inflammatory diseases, TREMFYA, a biologic for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, ERLEADA, a next-generation androgen recep...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters